Deutsche Bank AG Reaffirms “Hold” Rating for GlaxoSmithKline plc (GSK)
GlaxoSmithKline plc (LON:GSK)‘s stock had its “hold” rating reaffirmed by investment analysts at Deutsche Bank AG in a research note issued on Thursday.
Several other brokerages also recently issued reports on GSK. Beaufort Securities reissued a “buy” rating on shares of GlaxoSmithKline plc in a research note on Tuesday, August 2nd. Jefferies Group reissued a “buy” rating and issued a GBX 2,000 ($26.64) price objective on shares of GlaxoSmithKline plc in a research note on Friday, July 29th. BNP Paribas reissued a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Friday, July 29th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline plc in a research report on Thursday, July 28th. Finally, Sanford C. Bernstein set a GBX 1,755 ($23.38) target price on GlaxoSmithKline plc and gave the stock a “neutral” rating in a research report on Thursday, July 28th. Two analysts have rated the stock with a sell rating, eighteen have given a hold rating and seven have given a buy rating to the company. GlaxoSmithKline plc presently has a consensus rating of “Hold” and an average target price of GBX 1,655.84 ($22.05).
Shares of GlaxoSmithKline plc (LON:GSK) traded down 1.54% during trading on Thursday, hitting GBX 1599.50. The company’s stock had a trading volume of 7,824,068 shares. The company’s market capitalization is GBX 77.75 billion. The firm’s 50 day moving average is GBX 1,666.33 and its 200-day moving average is GBX 1,516.34. GlaxoSmithKline plc has a 1-year low of GBX 1,227.50 and a 1-year high of GBX 1,716.50.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/10/deutsche-bank-ag-reaffirms-hold-rating-for-glaxosmithkline-plc-gsk.html
The company also recently announced a dividend, which will be paid on Thursday, October 13th. Stockholders of record on Thursday, August 11th will be paid a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, August 11th. This represents a dividend yield of 1.12%.
In other news, insider Cartwright,Stacey bought 461 shares of the stock in a transaction dated Friday, July 1st. The stock was bought at an average cost of GBX 1,559 ($20.76) per share, with a total value of £7,186.99 ($9,572.44). Also, insider Slaoui,Moncef bought 28 shares of the stock in a transaction dated Friday, August 12th. The stock was purchased at an average cost of GBX 2,208 ($29.41) per share, with a total value of £618.24 ($823.44).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GlaxoSmithKline plc and related companies with MarketBeat.com’s FREE daily email newsletter.